Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern India

S Saravanan, M Vidya, P Balakrishnan… - Clinical infectious …, 2012 - academic.oup.com
Background. A cross-sectional study among individuals receiving second-line antiretroviral
treatment was conducted to report on the level of detectable viremia and the types of drug …

Genotypic HIV type-1 drug resistance among patients with immunological failure to first-line antiretroviral therapy in south India

M Vidya, S Saravanan, S Uma, N Kumarasamy… - 2009 - journals.sagepub.com
Background HIV type-1 (HIV-1) monitoring in resource-limited settings relies on clinical and
immunological assessment. The objective of this study was to study the frequency and …

Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients

L Rajesh, R Karunaianantham… - AIDS Research and …, 2009 - liebertpub.com
There is limited information on the prevalence and pattern of HIV drug-resistant mutations
(DRMs) among HIV-1-coinfected tuberculosis (TB) patients before and after antiretroviral …

One-, two-, and three-class resistance among HIV-infected patients on antiretroviral therapy in private care clinics: Mumbai, India

A Gupta, DG Saple, G Nadkarni, B Shah… - AIDS research and …, 2010 - liebertpub.com
HIV-infected patients receiving antiretroviral (ARV) therapy (ART) in India are not all
adequately virally suppressed. We analyzed ARV drug resistance in adults receiving ART in …

Prediction of drug-resistance in HIV-1 subtype C based on protease sequences from ART naive and first-line treatment failures in North India using genotypic and …

JS Toor, A Sharma, R Kumar, P Gupta, P Garg… - Antiviral research, 2011 - Elsevier
Genotyping reveal emergence of drug resistance (DR)-related mutations in HIV-1 protease
(PR) gene in the first-line treatment failure patients as per Stanford DR database. In order to …

Replicative fitness costs of nonnucleoside reverse transcriptase inhibitor drug resistance mutations on HIV subtype C

KL Armstrong, TH Lee, M Essex - Antimicrobial agents and …, 2011 - Am Soc Microbiol
Single-dose nevirapine (NVP) is quite effective in preventing transmission of the human
immunodeficiency virus (HIV) from mother to child; however, many women develop …

HIV subtype, epidemiological and mutational correlations in patients from Paraná, Brazil

MMG da Silva, FQ Telles, CA da Cunha… - The Brazilian Journal of …, 2010 - Elsevier
OBJECTIVE: Analyze patients with HIV infection from Curitiba, Paraná, their epidemiological
characteristics and HIV RAM. METHODS: Patients regularly followed in an ID Clinic had …

Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India

AJ Kandathil, R Kannangai, VP Verghese… - Indian journal of medical …, 2009 - Elsevier
Purpose: There has been an increase in the number of individuals administered
antiretroviral therapy (ART) in India but treatment outcome is hampered by increasing …

Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance

U Neogi, A Shet, R Shamsundar, ML Ekstrand - AIDS, 2011 - journals.lww.com
Prevalence of etravirine genotypic resistance was assessed among 92 HIV-1C-infected
patients failing nevirapine and efavirenz-based regimens from a cohort of 552 Indian …

Prevalence of HIV drug resistance mutation in the northern Indian population after failure of the first line antiretroviral therapy

S Sinha, RC Shekhar, H Ahmad, N Kumar… - Current HIV …, 2012 - ingentaconnect.com
There is limited information available about the prevalence and pattern of human
immunodeficiency virus (HIV) drug resistance mutations (DRMs) among antiretroviral …